Palvella Therapeutics Inc Revenue Growth Rates (PVLA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Palvella Therapeutics Inc   (NASDAQ: PVLA)
 

PVLA's Revenue Growth by Quarter and Year

Palvella Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PVLA/growth
https://api.csimarket.com/api/v1/companies/PVLA/fundamentals
https://api.csimarket.com/api/v1/companies/PVLA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PVLA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -1.65
2nd Quarter June -0.11
1st Quarter March -0.12
FY -1.88

PVLAs Annual Revenue
Palvella Therapeutics Inc 's Revenue in the fiscal year 2025 $ -0.39 millions
Palvella Therapeutics Inc 's Revenue in the fiscal year 2024 $ -0.63 millions
Palvella Therapeutics Inc 's Revenue in the fiscal year 2023 $ 42.81 millions
Palvella Therapeutics Inc 's Revenue in the fiscal year 2022 $ 25.90 millions
Palvella Therapeutics Inc 's Revenue in the fiscal year 2021 $ 31.42 millions




PVLA Revenue third quarter 2026 Y/Y Growth Comment
Palvella Therapeutics Inc in the third quarter 2026 recorded of $ -1.65 millions.

According to the results reported in the third quarter 2026, Palvella Therapeutics Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Palvella Therapeutics Inc ' s Revenue no change of 0% ranks overall at the positon no. in the third quarter 2026.


PVLA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY   -

Financial Statements
Palvella Therapeutics Inc 's third quarter 2026 Revenue $ -1.65 millions PVLA's Income Statement
Palvella Therapeutics Inc 's third quarter 2025 Revenue $ -0.08 millions Quarterly PVLA's Income Statement


PVLA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY (Year on Year)   -


Back to PVLA Growth rate Comparisons >> Back to PVLA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Palvella Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PVLA's III. Quarter Q/Q Revenue Comment
Recent accomplishment of -1.65 millions by Palvella Therapeutics Inc come out even worse considering the -0.11 millions a quarter before.

Within Major Pharmaceutical Preparations industry Palvella Therapeutics Inc achieved highest sequential Revenue growth. While Palvella Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PVLA's III. Quarter Q/Q Revenue Comment
Recent accomplishment of -1.65 millions by Palvella Therapeutics Inc come out even worse considering the -0.11 millions a quarter before.

Within Major Pharmaceutical Preparations industry Palvella Therapeutics Inc achieved highest sequential Revenue growth. While Palvella Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Palvella Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ -2.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
Palvella Therapeutics Inc ' has realized cumulative trailing twelve months of $ -2 millions in the Sep 30 2026 period.
The business is worsening as the cumulative is inflating from $ -0.43 millions for the period from Jun 30 2026 to Sep 30 2025 and $ -0.497 millions from the TTM period ending Sep 30 2025.

Palvella Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
Palvella Therapeutics Inc ' has realized cumulative trailing twelve months of $ -2 millions in the Sep 30 2026 period.
The business is worsening as the cumulative is inflating from $ -0.43 millions for the period from Jun 30 2026 to Sep 30 2025 and $ -0.497 millions from the TTM period ending Sep 30 2025.

Palvella Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PVLA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Cytokinetics Incorporated2,356.46%$ 2,356.457 millions
Roivant Sciences Ltd 2,135.58%$ 2,135.582 millions
Lipocine Inc 1,898.77%$ 1,898.771 millions
Vivos Inc1,438.05%$ 1,438.052 millions
Crispr Therapeutics Ag1,325.08%$ 1,325.084 millions
Meiragtx Holdings Plc1,074.15%$ 1,074.146 millions


About Palvella Therapeutics Inc Revenue Growth Rates (PVLA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Palvella Therapeutics Inc (CIK 1583648).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-448638
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Palvella Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.